Clinical trialsCompany release

Corvus says soquelitinib Phase 3 PTCL and Phase 2 atopic dermatitis trials remain on track

🇺🇸 Corvus Pharmaceuticals, Inc. (CRVS) · Thu 05 Nov 2026

The company's third-quarter update reports continued enrolment in both studies, cash of $202.9 million into Q2 2028, and plans to discuss expanding its ALPS programme with the FDA.

Corvus Pharmaceuticals reported third-quarter 2026 results on 5 November and updated investors on soquelitinib, its ITK inhibitor. Two trials are still enrolling: the registrational Phase 3 study in relapsed or refractory peripheral T-cell lymphoma (PTCL) and a Phase 2 study in atopic dermatitis.

Partner Angel Pharma in China is running further work in immune-mediated disease. It expects data from cohort 1 in atopic dermatitis in March 2027, and hidradenitis suppurativa data are expected in the first half of 2027. A Phase 2 asthma trial is due to start by the first quarter of 2027.

On finances, Corvus reported cash of $202.9 million, which it expects to fund operations into the second quarter of 2028.

The company also plans to meet the US Food and Drug Administration to discuss widening its ALPS programme to include more centres and paediatric patients. No further details of the programme or the planned meeting were given in the material available.

What it means for your team

  • The registrational PTCL study is still recruiting, so no pivotal efficacy data are available yet and any filing timing remains open.
  • Atopic dermatitis data from Angel Pharma's cohort 1 in March 2027 will be the next clinical readout from the partnered programme in China.
  • The planned FDA meeting on ALPS may bring a wider centre network and paediatric patients; regulatory teams should watch for the outcome.
  • Cash runway into Q2 2028 covers the near-term trial milestones.

Company's press release (SEC filing): Corvus Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Corvus Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →